AU7419501A - Use of riluzole or its salts for preventing and treating adrenoleukodystrophy - Google Patents

Use of riluzole or its salts for preventing and treating adrenoleukodystrophy

Info

Publication number
AU7419501A
AU7419501A AU7419501A AU7419501A AU7419501A AU 7419501 A AU7419501 A AU 7419501A AU 7419501 A AU7419501 A AU 7419501A AU 7419501 A AU7419501 A AU 7419501A AU 7419501 A AU7419501 A AU 7419501A
Authority
AU
Australia
Prior art keywords
riluzole
preventing
salts
adrenoleukodystrophy
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU7419501A
Inventor
Patrick Aubourg
Michel Dib
Jean-Marie Stutzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Aventis Pharma SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU7419501A publication Critical patent/AU7419501A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)

Abstract

The invention concerns the use or riluzole of one of is pharmaceutically acceptable salts for preventing and treating adrenoleukodystrophy.
AU7419501A 2000-06-05 2001-06-05 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy Pending AU7419501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007162A FR2809620B1 (en) 2000-06-05 2000-06-05 USE OF RILUZOLE OR ITS SALTS FOR THE PREVENTION AND TREATMENT OF ADRENOLEUCODYSTROPHY
PCT/FR2001/001729 WO2001093802A2 (en) 2000-06-05 2001-06-05 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy

Publications (1)

Publication Number Publication Date
AU7419501A true AU7419501A (en) 2001-12-17

Family

ID=8850967

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001274195A Ceased AU2001274195B2 (en) 2000-06-05 2001-06-05 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
AU7419501A Pending AU7419501A (en) 2000-06-05 2001-06-05 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001274195A Ceased AU2001274195B2 (en) 2000-06-05 2001-06-05 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy

Country Status (14)

Country Link
EP (1) EP1299102B1 (en)
JP (1) JP4848117B2 (en)
AT (1) ATE323486T1 (en)
AU (2) AU2001274195B2 (en)
CA (1) CA2409379C (en)
CY (1) CY1107048T1 (en)
DE (1) DE60118924T2 (en)
DK (1) DK1299102T3 (en)
ES (1) ES2260230T3 (en)
FR (1) FR2809620B1 (en)
IL (2) IL152989A0 (en)
MX (1) MXPA02011810A (en)
PT (1) PT1299102E (en)
WO (1) WO2001093802A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
CN1290166A (en) * 1998-01-09 2001-04-04 Mor－研究应用有限公司 Treatment of movement disorders
WO1999051097A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent

Also Published As

Publication number Publication date
DE60118924D1 (en) 2006-05-24
PT1299102E (en) 2006-08-31
JP2003535113A (en) 2003-11-25
FR2809620A1 (en) 2001-12-07
CA2409379C (en) 2009-08-18
DK1299102T3 (en) 2006-08-14
IL152989A (en) 2009-08-03
DE60118924T2 (en) 2007-01-11
WO2001093802A3 (en) 2002-03-07
ATE323486T1 (en) 2006-05-15
CA2409379A1 (en) 2001-12-13
CY1107048T1 (en) 2012-09-26
ES2260230T3 (en) 2006-11-01
FR2809620B1 (en) 2002-08-02
IL152989A0 (en) 2003-06-24
EP1299102B1 (en) 2006-04-19
AU2001274195B2 (en) 2005-12-01
WO2001093802A2 (en) 2001-12-13
JP4848117B2 (en) 2011-12-28
MXPA02011810A (en) 2004-05-17
EP1299102A2 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
AU4086101A (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
WO2000038786A3 (en) Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
ZA941525B (en) Use of riluzole in the treatment of nero-AIDS
PT1071422E (en) Association of riluzole and levodopa for the treatment of parkinson disease
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
BR0112212A (en) A combination of fbpase inhibitors and antidiabetic agents useful for treating diabetes.
GB9804886D0 (en) Therapeutic combination
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
AU7419501A (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
AU5311301A (en) Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
IL143280A0 (en) Use of riluzole for treating acoustic traumas
AU2001274195A1 (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
WO2002005796A3 (en) Use of a spla2 inhibitor for the treatment of sepsis
AU2001286228A1 (en) Polymer and its use for the treatment and/or prevention of hyperphosphoremia
AU2001219672A1 (en) Phenoxyethyl-thiourea-pyridine compounds and their use for the treatment of hiv-infections